Visit AROMICS’ newsroom to read our most recent news

read more

european research

european research

AROMICS has a clear international vision. From its inception, the company has participated in the establishment of a biotechnology strategy in Europe to improve commercial and production activities of small and medium size companies.

AROMICS has proven experience in European Projects under various EU funding programs (FP6, FP7 and Era-net). Supported by a grant of the Catalan Government, AROMICS set up a department to successfully perform funding, management and IP tasks with the goal of transforming the company into a more competitive, leading edge SME in the European arena.

The active participation of the company in European funded R&D projects as well as membership in different European platforms enables the company to:

  • Be at the forefront of European research.
  • Identify, improve and implant new technologies with potential applications in the health sector(industry and clinical practice).
  • Favor technology transfer.
  • Share the costs of innovation through partnerships with other biotechnology and pharmaceutical companies.

AUTOSCREEN. This project, started on January 1st 2007, aims to develop an innovative screening platform suitable for high-throughput and high-content cell-based assays and to demonstrate its suitability for high-resolution in situ techniques.



(Co-financed by the 6th Framework Programme of the European Communities)


CLEANHIVE. The main objective of CLEANHIVE is to develop a portable, cost-effective, easy to use and sensitive tool able to detect both Nosema species involved in the depopulation syndrome, to be used in field conditions by non-technical staff in the beekeeping sector in order to stop the spread of Nosema ceranae.



(Co-financed by the 7th Framework Programme of the European Communities)


HILYSENS. The project aims to develop a novel lab-on-chip diagnostic tool to improve clinical diagnostic, disease monitoring and treatment of Lyme Disease by enabling specific and sensitive detection of the human serological response against its causative agent Borrelia burgdoferi infections.



(Co-financed by the 7th Framework Programme of the European Communities)


SMART. The final goal of the project is the experimental validation (proof of concept) of a new method for the treatment of infectious diseases specifically targeting bacterial thymidylate synthase (TS) by recently patented compounds



(Co-financed by the EuroTransBio initiative)


ACCELEROMICS: This project, started on April 2011, aims to develop a novel antiviral for the treatment of Hepatitis C.


Invest in Spain C2-10-23

(Co-financed by Invest in Spain )


MSALS: The aim of the project is to develop a new treatment for Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS). The general objectives pursued by this project are to conduct preclinical studies to assess the efficacy of the proposed drug in an accepted animal model of ALS. It will also conduct a clinical trial in patients with Relapsing-Remitting MS to assess the efficacy and safety of the developed drug and finally the validation of genetic biomarkers of efficacy response of the proposed treatment and identify new therapeutic target in MS.


NUCLIS Technology InnovationProgram funding- 2010

(Co-financed by FEDER fund of the European Commission)